Back to today’s briefing

Story perspectives

FDA Approves Akeso's Cancer Drug Amid Trade Tensions

4/26/2025

50 3

Summary

Story summary

In a groundbreaking move, the FDA has greenlit Akeso's penpulimab-kcqx for advanced nasopharyngeal carcinoma, a triumph for the Chinese biotech amid rising US-China trade tensions. Additionally, Akeso's ivonescimab demonstrated potential against Merck's Keytruda in lung cancer trials, though mixed survival data left some investors wary. Akeso is poised to broaden its global footprint.

1 of 1

Story summary

In a groundbreaking move, the FDA has greenlit Akeso's penpulimab-kcqx for advanced nasopharyngeal carcinoma, a triumph for the Chinese biotech amid rising US-China trade tensions. Additionally, Akeso's ivonescimab demonstrated potential against Merck's Keytruda in lung cancer trials, though mixed survival data left some investors wary. Akeso is poised to broaden its global footprint.